摄入来自[具体来源未提及]的胞外聚合物可缩短感冒和流感症状的持续时间：一项随机、安慰剂对照干预研究。
Ingestion of Exopolymers from Reduces the Duration of Cold and Flu Symptoms: A Randomized, Placebo-Controlled Intervention Study.
作者信息
Lim Jong-Min, Do Eunju, Park Dong-Chan, Jung Go-Woon, Cho Hyung-Rae, Lee Seo-Young, Shin Jae Wook, Baek Kyung Min, Choi Jae-Suk
机构信息
Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil, Ilgwang-myeon, Busan 46048, Republic of Korea.
Korean Medicine Industry Support Center, Daegu Technopark, 136 Sincheondong-ro, Suseong-gu, Daegu 42158, Republic of Korea.
出版信息
Evid Based Complement Alternat Med. 2018 May 30;2018:9024295. doi: 10.1155/2018/9024295. eCollection 2018.
AIM
The objective of the study was to assess the efficacy of exopolymers from (EAP) on the incidence of colds and flu in healthy adults.
METHODS
We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30-70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and flu symptoms, a primary variable in assessing effectiveness, and serum cytokine levels as well as WBC counts as secondary variables were also evaluated.
RESULTS
EAP was associated with a statistically significant decrease in the duration of cold and flu symptoms, a primary variable in assessing effectiveness. Although cold and flu symptom levels were not significantly different at a significance level of 5%, the cold and flu symptom levels of the EAP group were less severe compared to the placebo group. No statistically significant changes of serum cytokine levels as well as WBC counts were observed.
CONCLUSION
The results showed that EAP is a useful pharmaceutical and functional food material for preventing and treating colds and flu.
目的
本研究的目的是评估[具体来源未明确，此处为EAP指代不明，推测是某种外聚合物（Exopolymers）]的外聚合物（EAP）对健康成年人感冒和流感发病率的疗效。
方法
在流感季节开始时，我们进行了一项随机、双盲、安慰剂对照研究。从普通人群中招募了76名受试者（年龄在30至70岁之间）。受试者被指示每天服用一粒EAP胶囊或一粒安慰剂，为期8周。还评估了感冒和流感症状的持续时间（评估有效性的主要变量）以及血清细胞因子水平和白细胞计数作为次要变量。
结果
EAP与感冒和流感症状持续时间的统计学显著降低相关，感冒和流感症状持续时间是评估有效性的主要变量。尽管在5%的显著性水平上感冒和流感症状水平没有显著差异，但与安慰剂组相比，EAP组的感冒和流感症状水平较轻。未观察到血清细胞因子水平和白细胞计数有统计学显著变化。
结论
结果表明，EAP是一种用于预防和治疗感冒和流感的有用药物和功能性食品原料。
Zotero 插件